Beijing, China, May 10, 2023 -  Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087. SH) is pleased to announce its 3mL insulin glargine pre-filled pen which is in cooperation with local Indian customers has been approved for marketing in India. This marks Gan & Lee's official commercialization license to sell insulin glargine-related products to India, further enriching the insulin glargine product choices for Indiandiabetic patients.

The approved insulin glargine pre-filled pen is a portable syringe device that is pre-filled with a 3mL insulin cartridge and can be disposed of as soon as it is used up, with the advantages of one-time use and easy carrying, aiming to provide a more convenient way of insulin injection for diabetic patients. Patients can adjust the dose knob to set the dosing amount from 1 to 60 units for injection, and the minimum scale of the pen is accurate to 1 unit, which can meet the daily insulin injection needs of diabetic patients by precisely controlling the drug dose. The design of the device can help patients reduce the occurrence of injection pain.

Located in southern Asia, India is the largest country in the South Asian subcontinent with a population of about 1.408 billion¹, the second largest in the world, and a per capita GDP of US$2,256.59². According to the International Diabetes Federation (IDF) Atlas 10th edition, as of 2021, approximately 74.2 million (aged 20-79) in India have diabetes, ranking the second highest in the world, with a prevalence of 8.3%. This number is expected to increase to 125 million by 2045. In addition, 39.4 million people in India are undiagnosed with diabetes, an undiagnosed rate of 53.1%³.

India is one of the key partners of China's "The Belt and Road" initiative and a key target country for Gan & Lee's “going global” strategy. The approval of the insulin glargine pre-filled pen is another significant development for Gan & Lee after the successful commercialization of the insulin glargine cartridge in the Indian market. This will be able to provide Indian patients with a more convenient, safe, and comfortable injection experience. In the future, Gan & Lee will continue to provide more high-quality diabetes treatment solutions for Indian patients, further strengthen the cooperation between China and India in the field of healthcare, and bring better medical and health services to the people of both countries.

References:

1. 中国外交部. (2023, January). 印度国家概况. 国家概况_中华人民共和国外交部. from https://www.fmprc.gov.cn/web/gjhdq_676201/gj_676203/yz_676205/1206_677220/1206x0_677222/

2. Data Commons. (2022, January 5). India. India - Place Explorer - Data Commons. Retrieved from https://datacommons.org/place/country/IND?utm_medium=explore&mprop=amount&popt=EconomicActivity&cpv=activitySource%2CGrossDomesticProduction&hl=en

3. IDF Diabetes Atlas 10th edition 2021. Available at: https://diabetesatlas.org/atlas/tenth-edition/

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.